Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Eukaryotic Gene Expression
Facteur d'impact: 2.156 Facteur d'impact sur 5 ans: 2.255 SJR: 0.649 SNIP: 0.599 CiteScore™: 3

ISSN Imprimer: 1045-4403
ISSN En ligne: 2162-6502

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukaryotGeneExpr.v13.i24.170
10 pages

Prostaglandin E—A Powerful Anabolic Agent for Generalized or Site-Specific Bone Formation

Yannis Vrotsos
Department of Periodontology, University of Athens School of Dentistry, Athens, Greece
Scott C. Miller
Division of Radiobiology, University of Utah, Salt Lake City, UT; and 3Department of Cell Biology, University of Massachusetts Medical School, Worcester, MA
Sandy C. Marks, Jr.
Department of Cell Biology, University of Massachusetts Medical Center, Worcester 01655, USA

RÉSUMÉ

Prostaglandins are locally secreted, rapidly metabolized, biologically active fatty acids first identified in the prostate. The role of prostaglandins in the inflammatory response has been widely studied. However, some prostaglandins, particularly those of the E series (PGEs), can suppress inflammation, making it difficult to understand the local events and their sequence. This bimodal potential of the PGEs has been poorly understood in skeletal biology, causing the initial report of PGEs as mediators of bone resorption to persist for more than two decades, despite ample evidence to the contrary. This resulted in part from the power of any initial report to overrule subsequent conflicting views and in part on the exclusive reliance on in vitro data to explain in vivo phenomena. Over a decade ago, the potential of PGEs as authentic anabolic skeletal agents was demonstrated convincingly in vivo by both systemic and local delivery. The potential clinical applications of the PGEs in skeletal biology have not yet been developed. Our purpose is to review the reasons for the delayed discovery of the true skeletal effects of the PGEs and to describe applications for this technology. With the development of appropriate delivery systems, one can anticipate widespread clinical applications of the PGEs to accelerate skeletal repair, and to treat skeletal pathologies and trauma.


Articles with similar content:

Stem Cells for Skin Tissue Engineering and Wound Healing
Critical Reviews™ in Biomedical Engineering, Vol.37, 2009, issue 4-5
Francois Berthiaume, Melissa Przyborowski, Ming Chen
Heparan Sulfate-based Treatments for Regenerative Medicine
Critical Reviews™ in Eukaryotic Gene Expression, Vol.21, 2011, issue 1
Victor Nurcombe, Bina Rai, Simon M. Cool
Progress Toward Skeletal Gene Therapy
Critical Reviews™ in Eukaryotic Gene Expression, Vol.14, 2004, issue 1&2
Henry J. Klamut, Shin-Tai Chen, David J. Baylink, K.-H. William Lau
New Derivatives of 5-Aminolevulinic Acid for Photodynamic Therapy: Chemical Synthesis and Porphyrin Production in In Vitro and In Vivo Biological Systems
Journal of Environmental Pathology, Toxicology and Oncology, Vol.25, 2006, issue 1-2
Aslak Godal, Jahn M. Nesland, Jon Erik Branden, Jo Klaveness, Nils O. Nilsen, Qian Peng
Nanostructured Lipid Carriers: A New Paradigm in Topical Delivery for Dermal and Transdermal Applications
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.34, 2017, issue 4
Gajanand Sharma, Bhupinder Singh, Kaisar Raza, Om Parkash Katare, Kanika Thakur